Company ProfilePremium

Kuraray Noritake Dental Inc.

Company Profile Analysis

クラレノリタケデンタル株式会社

ESOMAR 23 Corporate BadgeISO Certifications Badge
Kuraray Noritake Dental Inc. - Company showcase

Kuraray Noritake Dental Inc. Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Kuraray Noritake Dental Inc. Overview

Kuraray Noritake Dental is a Japanese dental-materials specialist formed in 2012 by fusing Kuraray's polymer-chemistry dental franchise (CLEARFIL adhesives and composites, PANAVIA resin cements, built on its proprietary MDP adhesive monomer) with Noritake's ceramic franchise (Noritake porcelains, CERABIEN, and the KATANA multilayer zirconia line). The combination gives it an unusual "organic + inorganic" footprint that spans both the dental clinic (adhesion, restoration, cementation) and the dental laboratory (veneering porcelain, zirconia discs and blocks, CAD/CAM materials). Its competitive identity rests on materials science — MDP is now treated as a global reference monomer used across the industry — and on proprietary in-house zirconia powder that enables ultra-fast sintering (a 9-minute chairside cycle for KATANA Zirconia ONE SPEED CROWN). It is a mid-sized, premium, technology-led player rather than a full-line distributor, competing against Ivoclar, Dentsply Sirona, Solventum (ex-3M Oral Care), GC and Tokuyama, and it is strategically backed by Kuraray's balance sheet and global sales network.


What the company does

KND develops, manufactures and sells dental materials and associated devices. Its stated line of business is "dental adhesives and filling materials, dental crown and bridge resin, dental ceramics, dental plaster, dental CAD/CAM devices and materials" (Kuraray press release, 7 Aug 2026; repeated in releases of 2018, 2019 and 2022).

At launch in 2012, the company described its mission as integrating Kuraray Medical's organic dental materials (bonding agents, fillings, facing resin) with Noritake Dental Supply's inorganic materials (crown ceramics, plaster) to develop materials with new functions and to accelerate global expansion beyond Japan (Kuraray press release, 2 Apr 2012).

Business model and revenue model

Revenue model: Overwhelmingly product sales (consumables and semi-finished restorative materials). Kuraray's group revenue recognition policy states that revenue from goods/products is recognized on delivery when the customer obtains control (Kuraray Report 2026, Financial Section, Note 5(5)). No subscription, service or licensing revenue line is disclosed for KND, though KND has an out-licensing programme on its multilayer ceramics patent (EP 2024300) — licensees include 3M (March 2018) and a German competitor (April 2022 settlement). Licensing income amounts are not publicly disclosed.

Product vs. service mix: Not publicly disclosed; independent characterization: >95% product sales, with education (seminars, webinars, hands-on courses) used as a demand-generation tool rather than a monetised service.

Channel: Sales through dental dealers/distributors and Kuraray group sales subsidiaries (Kuraray America, Kuraray Europe GmbH, Kuraray China, Kuraray Noritake Dental Brasil, Kuraray Asia Pacific). Clinical education is delivered in local languages in China and Brazil (Dental Tribune interview, 4 Mar 2026).

Value-chain position

KND sits upstream-to-midstream: it synthesizes key chemistries itself (MDP monomer; in-house zirconia raw powder — "we consistently develop and manage raw material powders in-house", Yamaguchi interview, Mar 2026) and converts them into finished branded consumables. It partners with milling-machine and sintering-furnace makers rather than selling heavy capital equipment itself (CAD/CAM "devices" are part of the licensed line of business, but no major proprietary hardware franchise is evident in recent disclosures).

Customer types and end-markets

Customer typeProducts usedEnd-market
General dentists / clinicsCLEARFIL bonds and composites, PANAVIA cements, TEETHMATE, KATANA chairside blocksRestorative and aesthetic dentistry
Dental laboratories / techniciansKATANA Zirconia discs, Noritake/CERABIEN porcelains, plaster and investmentsIndirect prosthetics (crowns, bridges)
Academic and KOL communityEvidence and education programmesOpinion leadership, specification
OEM / industry (indirect)MDP technology (licensed/recognized standard)Adhesive chemistry ecosystem

Company's own description vs. independent characterization

Company framing: KND emphasizes "durability" (preservation of strength and aesthetics), evidence-based information, and a "Universal Excellence" product concept — versatile materials that reduce components and steps in clinical workflows (Yamaguchi, Dental Tribune, 4 Mar 2026). Its IDS 2025 vision tagline was "The One. All Around." (ZWP Online, 30 Jan 2025).

Independent characterization: KND is a niche-premium materials innovator with two crown-jewel franchises — (1) MDP-based adhesion/cementation and (2) multilayer/high-speed zirconia — that is now pivoting from a Japan-and-Europe premium brand to a capacity-constrained global grower, with North American zirconia block demand as the primary volume driver (Kuraray press releases, 18 Dec 2023 and 7 Aug 2026). It lacks the scale, implant portfolio and equipment ecosystems of Dentsply Sirona or Straumann, and therefore competes on chemistry and quality rather than system lock-in.

Strategy

Stated themes (KND)

From the President's March 2026 interview and IDS 2025 materials:

  1. "Universal Excellence" — versatile, high-performance materials that minimize components and procedural steps; IDS 2025 vision "The One. All Around."

  2. Durability as core value — long-term preservation of strength and aesthetics in the oral environment.

  3. Evidence-based information infrastructure — systematically collecting internal/external data and case studies; multichannel scientific communication (congresses, journals, digital).

  4. Global expansion with regional tailoring — Europe as the quality/regulatory anchor; strategic expansion focus on the US, Asia and South America; local-language education in China and Brazil.

  5. Supply resilience and capacity — Miyoshi expansion, ultimately aiming to roughly double capacity; tighter manufacturing–R&D feedback loops.

  6. Collaborative development with clinicians and environmentally considerate product design (sustainability commitment, unquantified).

  7. Bioactive materials — development of products with bioactive properties for long-term predictable treatment (Newsweek/Worldfolio, Sep 2024).

  8. Digital/CX — new DX Promotion Department and CX Platform Design Group building CMS/DAM/PIM digital infrastructure (job postings).

Parent strategic frame

Kuraray's medium-term plan "PASSION 2026" (FY2022–FY2026) pursues three challenges: sustainability as an opportunity, innovation from networking, and transformation of people and organization (Kuraray Report 2026). Third-party summaries of the plan identify growing dental materials (including via acquisitions) as a growth priority (roic.ai profile summarizing Kuraray disclosures).

Initiatives in the last 24 months

InitiativeDateDetail
Miyoshi capacity expansionDecided Dec 2023; started Jun 2026+60 t/yr to 300 t/yr; approx. JPY 2.7 bn capex; expandable to 490 t/yr
KOL facility at Miyoshi2,026Top-floor reception and meeting space for visiting international KOLs
IDS 2025 launch waveMar 2025Three new products under "Universal Excellence"
Niigata plant transparency programmeFeb 2025Published factory video emphasizing hygiene/quality
DX / CX organization2025–2026New department per recruitment listings

Medium-term targets / guidance

KND: none publicly disclosed. Parent FY2026 guidance: net sales JPY 850.0 bn; operating income JPY 70.0 bn; ordinary income JPY 64.0 bn; net income JPY 40.0 bn; Functional Materials sales JPY 222.0 bn and OI JPY 14.5 bn (assumptions: JPY 150/USD, JPY 175/EUR) (Kuraray Report 2026). Kuraray shareholder-return policy from FY2025: total return ratio of 50% or more with progressive dividends and continuous buybacks (roic.ai summary of Kuraray disclosures).

Products & Services

Note: KND does not publish list prices globally; pricing is dealer-set.

Clinic (organic) materials

Brand / productDescriptionKey capabilityTarget customerLaunch / latest versionNotes
CLEARFIL (franchise)Adhesive and restorative family since 1978MDP-based bonding; top Japanese domestic share in bonding agents and fillings (as of 2012)Dentists1978 (CLEARFIL BOND SYSTEM F)Kuraray release 2 Apr 2012
CLEARFIL Universal Bond Quick 2Universal one-bottle adhesiveRapid application, universal etching modesDentistsIDS 2025Dental Tribune Mar 2026
CLEARFIL SE BOND / SE BOND 2Two-step self-etch adhesive, reference product in literatureMDP self-etch chemistryDentistsSE Bond late 1990s; SE Bond 2 mid-2010s—
CLEARFIL MAJESTY familyResin composites (ES-2, ES Flow etc.)Shade simplification, aestheticsDentistsOngoingkuraraynoritake.eu
CLEARFIL MAJESTY ES Flow UniversalFlowable compositeUniversal shading, simplified workflowDentistsIDS 2025Dental Tribune Mar 2026
PANAVIA (franchise)Resin cements built on MDPBonds to tooth, metals and zirconiaDentists1980s origin—
PANAVIA V5Adhesive resin cement systemEsthetic cementation, wide indicationDentistsFeatured on EU site; mid-2010skuraraynoritake.eu
PANAVIA SA Cement UniversalSelf-adhesive cementNo separate primer needed (claimed)Dentists~2020—
TEETHMATE (Desensitizer, F-1)Hypersensitivity / fluoride products; bioactive directionCalcium-phosphate based sealingDentists—Bioactive R&D direction per Yamaguchi 2024
Facing resins for crowns and bridgesIndirect composite resins (e.g.; ESTENIA C&B)Lab veneeringLabsOngoingLine of business

Laboratory and CAD/CAM (inorganic) materials

Brand / productDescriptionKey capabilityTarget customerLaunch / latest versionNotes
KATANA Zirconia (discs)Multilayer zirconia for lab millingFour-layer color gradation; precise shrinkage controlLabs2,012Protected by EP 2024300
KATANA Zirconia high-translucency series (STML/UTML)Enamel-like translucency for anteriorAesthetic monolithic restorationsLabs2,015Kuraray release 2019
KATANA Zirconia YMLMulti-yttria multilayer discUpper layers translucent; lower layers higher yttria-differentiated strengthLabs~2020Dental Tribune Mar 2026
KATANA Zirconia BlockChairside zirconia blocksShort treatment times; North American demand driverDentists (chairside)—Newsweek/Worldfolio Sep 2024
KATANA Zirconia ONE SPEED CROWNUltra-fast sintering zirconia9-minute sintering via highly activated powderDentists (chairside)RecentDental Tribune Mar 2026
CERABIEN ZRVeneering porcelain for zirconiaShade matchingLabs——
CERABIEN MiLaiNew ceramic powder range"Universal Excellence" porcelain systemLabsIDS 2025Dental Tribune Mar 2026
Noritake Super Porcelain (AAA / EX-3)Porcelain-fused-to-metal ceramicsCreated the modern veneering ceramic categoryLabs1987 (product naming discrepancy noted)—
Dental plaster and investmentsModel and casting materialsHeritage Noritake technologyLabs1939 origin—
CAD/CAM devicesZirconia frame production systemsHistoric Noritake CAD/CAMLabsLegacyLine of business

Services

Hands-on seminars, webinars in local languages (China, Brazil), KOL reception and meeting facilities on the top floor of the new Miyoshi building (opened 2026), journal and congress communication (Kuraray release, 7 Aug 2026; Dental Tribune, Mar 2026). Not monetised separately.

Financial Narrative

Disclosure status for KND

Because KND figures are unavailable, the tables below present the parent, Kuraray Co., Ltd. (consolidated, JGAAP, FY ending 31 Dec, JPY millions) as the financial backstop. Sources: Kuraray Report 2025 and 2026 (11-Year Financial Summary and Financial Section); StockAnalysis.com for gross profit, capex and D&A where cross-checked against Kuraray statements.

Income statement — Kuraray Co., Ltd.

Q1 FY2026 cumulative EPS reported at JPY 6.30 (Matsui Securities data).

Margins — Kuraray Co., Ltd. (%; computed from 6.1)

Revenue CAGR FY2021–FY2025: approx. 6.5% (computed: (808,447/629,370)^(1/4) − 1).

Dividends — Kuraray Co., Ltd.

Source: Kuraray Report 2026, Note 8 (FY2025 year-end JPY 27 proposed to AGM 26 Mar 2026).

Balance sheet — Kuraray Co., Ltd.

Total net assets, longer series (JPY M): FY2021 579602; FY2022 668534; FY2023 736156; FY2024 781790; FY2025 755175 (Kuraray Report 2025/2026). Net debt including lease liabilities per StockAnalysis: FY2021 151641; FY2022 195829; FY2023 147402; FY2024 122590; FY2025 176602.

Ratios — Kuraray Co., Ltd. (computed)

ROIC and cash conversion cycle: not computed (insufficient verified inputs).

Commentary

Parent trend. Kuraray grew sales strongly in FY2021–FY2022 (+16% and +20%) on post-COVID recovery, price pass-through and the full contribution of acquisitions (Calgon Carbon), then plateaued at JPY 780–830 bn. FY2025 was an inflection downward: sales −2.2% and operating income −30.8% to JPY 58.9 bn, as Vinyl Acetate (PVOH, PVB) suffered weak European demand, inventory valuation losses and raw material inflation, and extraordinary impairments (JPY 29.6 bn, chiefly Isoprene Chemicals JPY 15.0 bn and styrenic elastomers JPY 10.6 bn) cut net income 76.5% to JPY 7.5 bn. Free cash flow compressed to JPY 4.4 bn as capex jumped to JPY 94.2 bn while Kuraray simultaneously spent JPY 30.0 bn on buybacks and JPY 17.4 bn on dividends — funded by an increase in short-term borrowings and commercial paper. Leverage remains modest (net debt/EBITDA ~1.2x).

Read-across to KND. The dental business is one of the few positive commentary points in Kuraray's FY2025 review: "Medical" sales of cosmetic dental materials stayed brisk in Europe and the US, with stepped-up marketing. KND is therefore, by inference, a margin-accretive, growth-oriented asset inside a parent whose commodity-exposed businesses are under pressure — a pattern that makes it strategically more important to Kuraray than its likely size suggests. KND's own revenue scale is not publicly disclosed.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Internal Business Details

Internal business (characterization)ContentsMain production site

Organic / clinic materials (ex-Kuraray Medical)

Bonding agents, composite resins, resin cements, desensitizers, facing resins

Niigata Plant (Tainai)

Inorganic / laboratory and CAD/CAM materials (ex-Noritake Dental Supply)

Zirconia discs and blocks, veneering porcelains, plaster and investments

Miyoshi Plant (Aichi)

Revenue by Segment and Segment Margins & Growth (%)

MetricFY2024FY2025FY2026F

Functional Materials net sales (JPY Bn, as reported)

208.0206.9—

Functional Materials operating income (JPY Bn, as reported)

12.910.8—

Functional Materials net sales (JPY Bn, restated new definition)

—207.8222.0

Functional Materials operating income (JPY Bn, restated new definition)

—8.914.5

Functional Materials operating margin (%, as reported)

6.25.2—

Segment Revenue

SegmentFY2024 SalesFY2025 SalesFY2024 OIFY2025 OIFY2025 % of group sales

Vinyl Acetate

414.9404.587.662.550.0

Isoprene

76.480.4-9.5-4.99.9

Functional Materials (incl. dental)

208.0206.912.910.825.6

Fibers and Textiles

62.760.71.22.67.5

Trading

67.668.85.96.08.5

Others

50.940.82.31.85.0

Elimination & Corporate

-53.5-53.7-15.4-20.1—

Total

826.9808.485.158.9100

Knd Metric Details

KND metricStatus

EPS, DPS

Not applicable (unlisted)

Statutory public notice (kessan koukoku)

Japanese companies must publish summarized balance sheets; no KND notice was located in this research — not publicly disclosed

Income Statement

MetricFY2021FY2022FY2023FY2024FY2025

Net sales (JPY Mn)

629,370756,376780,938826,895808,447

Gross profit (JPY Mn)

204,136241,663239,982267,520246,508

Operating income (JPY Mn)

72,25687,13975,47585,08158,882

Depreciation and amortization (JPY Mn)

59,00365,45677,16385,26084,702

EBITDA = OI + D&A (JPY Mn)

131,259152,595152,638170,341143,584

Ordinary income (JPY Mn)

68,76584,06069,02581,48051,515

Income before income taxes (JPY Mn)

58,69677,99561,27353,17619,821

Net income attributable to owners (JPY Mn)

37,26254,30742,44631,7247,468

Margin Analysis (%)

MetricFY2021FY2022FY2023FY2024FY2025

Gross margin (%)

32.432.030.732.430.5

Operating margin (%)

11.511.59.710.37.3

EBITDA margin (%)

20.920.219.520.617.8

Net margin (%)

5.97.25.43.80.9

Per-Share Data

MetricFY2024FY2025

Interim DPS (JPY)

2727

Year-end DPS (JPY)

2727

Annual DPS (JPY)

5454

Balance Sheet

MetricFY2024FY2025

Total assets (JPY Mn)

1,291,2381,303,511

Cash and deposits (JPY Mn)

118,068104,102

Cash and cash equivalents per CF statement (JPY Mn)

121,692108,314

Short-term debt incl. CP and current LTD and bonds (JPY Mn)

51,99688,732

Long-term debt: bonds + long-term borrowings (JPY Mn)

192,286196,187

Total financial debt ex-leases (JPY Mn)

244,282284,919

Net debt ex-leases (JPY Mn)

122,590176,605

Shareholders' equity + AOCI (JPY Mn)

764,011742,620

Total net assets (JPY Mn)

781,790755,175

Goodwill (JPY Mn)

53,59152,212

Total intangible fixed assets incl. goodwill (JPY Mn)

115,898110,630

Working capital: current assets − current liabilities (JPY Mn)

367,031350,174

Cash Flow

MetricFY2021FY2022FY2023FY2024FY2025

Operating cash flow (JPY Mn)

78,22151,727129,298138,29498,591

Capex: purchase of PP&E and intangibles (JPY Mn)

68,40871,63559,02771,38394,177

Free cash flow = OCF − capex (JPY Mn)

9,813-19,90870,27166,9114,414

Dividends paid (JPY Mn)

———17,29217,367

Share buybacks (JPY Mn)

———20,00430,004

Returns & Leverage Ratios (%) and Financial Ratios (x)

MetricFY2024FY2025

ROE (%; NI / avg equity, FY2025 only computable here)

—1.0

ROA (%; OI / avg total assets)

—4.5

Current ratio (x)

2.852.53

Debt / total net assets (x)

0.310.38

Net debt / EBITDA (x)

0.721.23

Interest coverage: OI / interest expense (x)

31.121.0

Asset turnover (x; sales / avg assets)

—0.62

Region Overview

RegionRole / trend (company statements)Source

North America

Fastest-growing zirconia block market; primary rationale for Miyoshi expansion; preference for treatment efficiency

Kuraray releases Dec 2023 and Aug 2026; Yamaguchi Mar 2026

Europe

Brisk cosmetic dental sales FY2025; quality/regulatory lead market (MDR); preference for natural aesthetics

Kuraray Report 2026; Yamaguchi Mar 2026

Japan

Historic home market; top domestic share in bonding agents and fillings (2012 claim) and leading share in porcelains

Kuraray release Apr 2012

China

Regional office; among fastest-growing dental markets; rapid CAD/CAM adoption

Yamaguchi Mar 2026

Brazil / South America

Regional office (Kuraray Noritake Dental Brasil); balance of aesthetics and cost

Yamaguchi Mar 2026; CB Insights

Rest of Asia, Middle East

Covered via Kuraray Asia Pacific (Singapore) and new Kuraray Middle East regional office (2026)

Kuraray news archive 2026

Revenue by Region (%)

MetricFY2024FY2025

Overseas sales ratio (%)

79.280.0

Japan sales (%; derived as 100 − overseas)

20.820.0

Capital Markets

ItemValueSource / date

Share price

JPY 1,819.5

StockAnalysis, close 24 Jul 2026

Shares issued (end-FY2025)

307,963 thousand (treasury 924 thousand)

Kuraray Report 2026

Market cap (computed at JPY 1,819.5)

approx. JPY 558.6 bn

Computed

Market cap (third-party, date not stated)

JPY 513.7–523.5 bn

Finboard

Annual DPS FY2025

JPY 54

Kuraray Report 2026

Shareholder return policy

Total return ratio ≥50%, progressive dividends, continuous buybacks (from FY2025)

roic.ai summary of Kuraray disclosures

Buybacks

JPY 20.0 bn (FY2024); JPY 30.0 bn (FY2025); new buyback decision announced Feb 2026

Kuraray Report 2026; Kuraray news

Bonds outstanding

JPY 50.0 bn (end-FY2025)

Kuraray Report 2026

Capital Markets — Bonds

MetricWithin 1 yr1–2 yrs2–3 yrs3–4 yrs4–5 yrsOver 5 yrs

Bonds (JPY Mn)

010,00010,000020,00010,000

Long-term borrowings (JPY Mn)

32,61217,61223,57530,00010,00065,000

Analyst Conclusions

Guidance

KND: no public guidance. Parent FY2026: sales JPY 850 bn (+5.1%), OI JPY 70 bn (+18.9%), NI JPY 40 bn; Functional Materials OI to rise from JPY 8.9 bn (restated) to JPY 14.5 bn.

Bull case

  1. Capacity unlocks growth: the June 2026 Miyoshi line (+25% capacity to 300 t/yr, with a path to 490 t/yr) directly targets the fastest-growing demand pocket, North American zirconia blocks.

  2. Technology moat: MDP standard status, upheld multilayer IP with licensing income, and 9-minute sintering powder give KND defensible differentiation in both adhesion and ceramics.

  3. Strategic value to parent: with Kuraray's commodity segments under pressure (FY2025 OI −30.8%), the brisk-selling dental business is a likely priority for capital and could be re-rated within the group's portfolio.

Bear case

  1. Zirconia commoditization: Chinese and European low-cost multilayer discs erode price premiums; litigation history shows sustained imitation.

  2. Scale disadvantage: without implants, imaging or proprietary CAD/CAM hardware, KND depends on partners whose ecosystems may favour their own materials.

  3. Parent constraints and opacity: Kuraray's lower FY2025 earnings, rising debt and buyback commitments may limit KND's investment pace; lack of disclosure prevents investors from valuing or tracking the business.

Catalysts and monitorables (next 12 months)

  • Kuraray H2/FY2026 results (Feb 2027): any quantified commentary on Medical/dental.

  • Announcement of Kuraray's post-PASSION 2026 medium-term plan (expected late 2026–early 2027), especially any dental growth targets or M&A appetite.

  • Decision on Miyoshi Phase 2 (toward 490 t/yr).

  • New launches ahead of IDS 2027 (Cologne, March 2027).

  • Any change in the Kuraray/Noritake 66.7/33.3 ownership (Noritake is restructuring its own portfolio).

  • Bioactive product launches; patent opposition outcomes.

Analyst verdict

Kuraray Noritake Dental is best understood not as a public company but as a high-quality, privately held technology franchise embedded inside a listed chemical conglomerate. Its value rests on two durable assets: the MDP adhesion platform that underpins CLEARFIL and PANAVIA and has become an industry reference, and a proprietary zirconia materials platform — from raw powder to multilayer design to ultra-fast sintering — that has been commercially validated (KATANA since 2012), legally validated (EP 2024300 upheld in 2021) and monetized (licences to 3M and a German competitor). The company's recent behaviour is that of a business coming out of supply constraint: the 2023 decision and 2026 start-up of a JPY 2.7 bn Miyoshi line, explicitly justified by North American zirconia block demand, plus a stated ambition to roughly double ceramic capacity over time.

The central analytical problem is visibility. No revenue, margin, R&D or headcount data are disclosed, and Kuraray buries dental within a Functional Materials segment dominated by methacrylate and activated carbon. The only hard performance signal is qualitative but meaningful: in a year when Kuraray's operating income fell 31% and net income fell 77%, management singled out dental sales as brisk in Europe and the US. That suggests KND is among the group's healthier, structurally growing businesses.

On balance, KND appears strategically strong and operationally improving, with risks concentrated in zirconia price competition, two-plant concentration in Japan and dependence on its parent's capital allocation during a difficult earnings period. For investors, exposure is only available indirectly through Kuraray (where dental is a minority of earnings) or Noritake (33.3% equity interest). For partners, distributors and competitors, KND should be treated as a premium, IP-protected, capacity-expanding materials specialist whose influence on adhesive and zirconia standards exceeds its size. Any quantitative valuation requires data not currently in the public domain.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameTitleTenurePrior roles

Satoshi Yamaguchi

President (Representative)

From between Aug 2019 and Jul 2021 to present

Kuraray medical development division (R&D); marketing at Kuraray America; development role in Japan; Head of Dental Business, Kuraray Europe (Germany)

Kiyoyuki Arikawa

Former President

By Sep 2016 – by mid-2021

—

Sadaaki Matsuyama

First President (2012); previously President of Kuraray Medical

2012 – c.2016

Later Representative Director and Senior Managing Executive Officer of Kuraray; stepped down as Kuraray representative director (announced 27 Nov 2019)

“—” = not publicly disclosed.

Major Shareholders

HolderStake

Kuraray Co., Ltd.

66.7%

Noritake Co., Limited

33.3%

Competitive Landscape

Key Competitors

CompetitorListingOverlap with KNDPositioning vs. KND

Ivoclar Vivadent (Ivoclar Group)

Private (Liechtenstein)

Ceramics (IPS e.max), zirconia, adhesives, composites

Leader in lab ceramics; broader system incl. furnaces

Dentsply Sirona

NASDAQ: XRAY

CAD/CAM (CEREC), adhesives, cements, zirconia

Much larger; equipment ecosystem; KND zirconia blocks run on partner mills

Solventum (former 3M Health Care, Oral Care)

NYSE: SOLV

Adhesives (Scotchbond), cements (RelyX), composites (Filtek), zirconia (Lava)

Major adhesive competitor; also a KND patent licensee

GC Corporation

Private (Japan)

Composites, glass ionomers, cements, ceramics, CAD/CAM

Closest Japanese full-line rival

Tokuyama Dental (Tokuyama Corp. subsidiary)

Parent TSE: 4043

Composites (Estelite), adhesives

Japanese composite specialist

Shofu Inc.

TSE: 7979

Composites, ceramics, CAD/CAM blocks

Japanese mid-size peer

Kulzer (Mitsui Chemicals)

Parent TSE: 4183

Composites, adhesives, lab materials

Owned by another Japanese chemical major

VOCO GmbH

Private (Germany)

Composites, adhesives, CAD/CAM blocks

Value-oriented clinic materials

Coltene

SIX: CLTN

Composites, adhesives

Smaller European player

Envista (Kerr, Nobel)

NYSE: NVST

Adhesives/composites (Kerr), restorative

Broader portfolio incl. implants

Dentsply/Straumann zirconia & Chinese zirconia makers (e.g., Aidite, Upcera)

Various

Zirconia discs

Price competition in multilayer zirconia

Kettenbach Dental

Private

Impression materials, restoratives

Partial overlap

Company Snapshot

$5,400.4M

Revenue

Tokyo, Japan

Headquarters

SWOT Analysis

Strengths

  • MDP leadership: Kuraray's MDP monomer is recognized as a global standard adhesive monomer used widely by other manufacturers (Yamaguchi, Dental Tribune, Mar 2026).
  • Upheld zirconia IP: EP 2024300 survived a nullity action in full (German Federal Patent Court, Jun 2021, final) and generated licences with 3M (2018) and a German competitor (2022).
  • Proprietary zirconia powder: enables a 9-minute sintering cycle for KATANA Zirconia ONE SPEED CROWN (Mar 2026).
  • Brand longevity: CLEARFIL since 1978; Noritake dental since 1939; PANAVIA, KATANA, CERABIEN all established brands.
  • Strong parent: Kuraray FY2025 sales JPY 808.4 bn, net debt/EBITDA ~1.2x, OCF JPY 98.6 bn (Kuraray Report 2026).
  • Wide reach: supply to 90+ countries from two Japanese plants (Feb 2025).
  • Growth signal inside parent: Medical dental sales described as brisk in Europe/US in FY2025 while most Kuraray businesses declined.

Weaknesses

  • Opacity: no standalone financial disclosure, limiting stakeholder visibility.
  • Concentrated manufacturing: only two production sites (Miyoshi, Niigata), both in Japan (Aug 2026 release) — natural-disaster and FX concentration.
  • Capacity constraint history: expansion needed because Miyoshi production was "ramping up" with rising demand (Dec 2023), indicating prior tightness.
  • Small organization: 101–500 employees (Mynavi bracket), ~350 in 2016, versus multinational competitors.
  • No hardware/implant ecosystem: relies on third-party mills and furnaces (Yamaguchi, Mar 2026).
  • JV governance complexity: 66.7/33.3 ownership with Noritake may slow strategic decisions (structural; no specific dispute disclosed).

Opportunities

  • North American zirconia blocks: explicitly the fastest-growing demand pocket (Aug 2026 release).
  • Headroom at Miyoshi: expandable from 300 to 490 t/yr (Aug 2026 release).
  • China and Brazil: described as among the fastest-growing dental markets with rapid CAD/CAM adoption (Mar 2026).
  • Bioactive materials pipeline (Sep 2024).
  • Licensing monetization of multilayer and other patents (2018, 2022 precedents).
  • Parent's new regional hubs: Singapore technical center (2025), Middle East office (2026).

Threats

  • Low-cost zirconia competitors (industry structure; patent disputes in 2019–2022 show imitation pressure).
  • Large-cap rivals' bundling: Dentsply Sirona (CEREC ecosystem), Solventum, Ivoclar.
  • Parent profit pressure: Kuraray FY2025 OI −30.8% and NI −76.5% could constrain capital allocation or push portfolio reviews.
  • Regulatory burden: EU MDR strictness acknowledged by KND (Mar 2026).
  • FX: yen appreciation would reduce yen value of a ~80% overseas-oriented group (Kuraray overseas ratio 80.0%, FY2025).
  • Patent oppositions: competitor oppositions against KND patents (2019 and 2023 grants) (GreyB).

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
30 Jan 2025KND announces IDS 2025 presence (Hall 11.3) under "Universal excellence" / "The One. All Around."Sets 2025 product narrative
18 Feb 2025Niigata Plant behind-the-scenes video published; supply to 90+ countriesQuality/supply messaging
25–29 Mar 2025IDS Cologne: launches CLEARFIL MAJESTY ES Flow Universal, CLEARFIL Universal Bond Quick 2, CERABIEN MiLaiLargest product refresh in years
Jul 2025 (parent)Kuraray reduces MMA and some downstream methacrylate capacityWeighs on Functional Materials segment (not dental)
2025 (parent)Kuraray Asia Pacific Technical Center established in SingaporeAPAC technical support infrastructure
Q4 2025 (parent)Kuraray books JPY 29.6 bn impairments (Isoprene Chemicals, styrenic elastomers)Parent profit hit; dental unaffected
1 Jan 2026 (parent)Kuraray major organizational changes take effectContext for centenary-year restructuring
Feb 2026 (parent)Kuraray FY2025 results: sales −2.2%, OI −30.8%; Medical (dental) sales "brisk" in Europe/USConfirms dental as a bright spot
Feb 2026 (parent)Kuraray decision to launch a share buyback (exact date/amount per Kuraray IR)Capital return
2026 (parent)Kuraray establishes Middle East regional officePotential new dental distribution reach
4 Mar 2026President Yamaguchi interview published (Dental Tribune): Miyoshi doubling ambition, MDP, zirconia technology, regional strategyMost detailed recent strategic disclosure
26 Mar 2026 (parent)Kuraray AGM; year-end dividend JPY 27—
27 Mar 2026 (parent)Kuraray Corporate Governance Report filed—
1 Apr 2026 (minority owner)Noritake integrates Tableware into Ceramics & Materials businessNoritake restructuring; no disclosed impact on KND stake
May 2026 (parent)Kuraray Report 2026 published, incl. FY2026 guidance and segment redefinitionFunctional Materials now includes Electronics Materials
Jun 2026New Miyoshi production line starts operation+60 t/yr; total 300 t/yr
24 Jun 2026 (parent)Kuraray marks 100th anniversary with ceremonyBrand moment used in dental marketing
7 Aug 2026Press release on Miyoshi line start-up; capex approx. JPY 2.7 bn; KOL facilitiesCapacity for North American zirconia block demand
Aug 2026 (parent)Monitor dental commentary

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

2 charts
Revenue by Segment: Functional Materials net sales fell from JPY 208 Bn in FY2024 to JPY 206.9 Bn in FY2025.
Kuraray Noritake Dental Inc. — Revenue by Segment
Series (JPY Bn)FY2024FY2025FY2026F
Functional Materials net sales208206.9—
Functional Materials operating income12.910.8—
Functional Materials net sales—207.8222
Functional Materials operating income—8.914.5

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. Kuraray Co., Ltd., "Kuraray Noritake Dental Inc. Launched", 2 Apr 2012 (kuraray.com)
  2. Kuraray / Noritake, integration notice, 28 Jan 2011 (kuraray.com)
  3. Kuraray presentation on KND, 13 Sep 2016 (kuraray.co.jp)
  4. Kuraray, "Expanding Production Capacity at KND's Miyoshi Plant", 18 Dec 2023 (kuraray.com)
  5. Kuraray, "New Production Line at KND's Miyoshi Plant Begins Operations", 7 Aug 2026 (kuraray.com)
  6. Kuraray, KND patent licence with 3M, 17 May 2018 (kuraray.com)
  7. Kuraray, KND files patent suit in Germany, Aug 2019 (kuraray.com)
  8. Kuraray, KND settles patent suit, 29 Jun 2022 (kuraray.com)
  9. Aegis Dental Network, KND–B&D Dental licence, 23 Sep 2021 (aegisdentalnetwork.com)
  10. Kuraray Noritake Europe, "Kuraray turns 100" (Dental Tribune interview, 4 Mar 2026) (kuraraynoritake.eu)
  11. Kuraray Noritake Europe, "Kuraray Noritake leads dental innovation" (Newsweek/Worldfolio, Sep 2024) (kuraraynoritake.eu)
  12. Kuraray Noritake Europe, About / history pages · kuraraynoritake.eu
  13. Kuraray Noritake Europe, Niigata factory video, 18 Feb 2025 (kuraraynoritake.eu)
  14. ZWP Online, Kuraray at IDS 2025, 30 Jan 2025 (zwp-online.info)
  15. Kuraray Report 2026, Financial Section (kuraray.com)
  16. Kuraray Report 2026, At a Glance / Global Portfolio · kuraray.com
  17. Kuraray Report 2025, 11-Year Financial Summary and corporate data · kuraray.co.jp
  18. StockAnalysis, Kuraray income statement, balance sheet, cash flow (accessed via search, Jul 2026) (stockanalysis.com)
  19. Finboard, Kuraray income statement (finboard.jp)
  20. roic.ai, Kuraray profile (roic.ai)
  21. Kuraray news archive 2025–2026 (kuraray.com)
  22. JPX disclosure, Kuraray representative director change, 27 Nov 2019 (www2.jpx.co.jp)
  23. Mynavi Agent, KND company profile (mynavi-agent.jp)
  24. Doda job listing (KND DX Promotion Dept.) (doda.jp)
  25. GreyB IPverse, KND opposition analysis (ipverse.greyb.com)
  26. CB Insights (Kuraray Noritake Dental Brasil listing) (cbinsights.com)
  27. Envalith, Noritake Co., Limited overview (Jul 2026) (envalith.com)

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.